PCNA and neoplasm: Given these limitations associated with standard CsPt treatment and the high sensitivity of DDTD lymphoma to low concentrations of CsPt in vitro, we predicted that tumor-specific defects in PCNA ubiquitination could actually chemosensitize those tumors to lower doses of CsPt in vivo.